Literature DB >> 29616115

Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.

Yuichi Imai1,2,3, Kosei Hasegawa1,2, Hirokazu Matsushita4, Nao Fujieda4, Sho Sato1,2, Etsuko Miyagi3, Kazuhiro Kakimi4, Keiichi Fujiwara1,2.   

Abstract

Expression of immune checkpoint molecules, including programmed cell death protein-1 (PD-1), has been reported on T cells in various types of cancer. However, the expression status of these molecules in the tumor microenvironment of epithelial ovarian cancer (EOC) has not yet been studied. A total of 54 cases of malignant ascites from patients with EOC were analyzed in the present study. The expression of PD-1, lymphocyte-activation gene-3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and B and T lymphocyte attenuator (BTLA) on cluster of differentiation (CD)4+ and CD8+ T cells in malignant EOC ascites were investigated using multicolor flow cytometric analysis. The expression of PD-L1 in tumor cells, PD-L2 in HLA-DR-positive cells and galectin-9 in ascitic fluid was also analyzed. In addition, cytokine profiling of ascitic fluid was performed to understand the immune microenvironment of EOC. PD-1, LAG-3 TIM-3, and BTLA were expressed on 65.8, 10.6, 4.3 and 37.6% of CD4+ T cells, and on 57.7, 5.0, 4.9 and 15.7% of CD8+ T cells, respectively. Programmed cell death protein-1 (PD-1), LAG-3 and BTLA were more frequently expressed on CD4+ compared with CD8+ T cells. The co-expression of immune checkpoints was further investigated and results indicated that 39 (72.2%) and 37 patients (68.5%) expressed multiple immune checkpoints on CD4+ T cells and CD8+ T cells, respectively. In addition, lower levels of TNF-α and interleukin-6 in ascitic fluid were significantly associated with multiple immune checkpoint expression on CD8+ T cells. The present findings indicated that multiple immune checkpoint molecules were expressed on T cells in the EOC tumor microenvironment and the results may suggest the significance of simultaneous blockade of immune checkpoints to control EOC.

Entities:  

Keywords:  B and T lymphocyte attenuator; T-cell immunoglobulin and mucin-domain containing-3; ascites; lymphocyte-activation gene-3; ovarian cancer; programmed cell death protein-1

Year:  2018        PMID: 29616115      PMCID: PMC5876465          DOI: 10.3892/ol.2018.8101

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.

Authors:  Barry Rosen; Stephane Laframboise; Sarah Ferguson; Jason Dodge; Marcus Bernardini; Joan Murphy; Yakir Segev; Ping Sun; Steven A Narod
Journal:  Gynecol Oncol       Date:  2014-07-12       Impact factor: 5.482

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

Review 5.  Immune checkpoint inhibitors: a patent review (2010-2015).

Authors:  Matthieu Collin
Journal:  Expert Opin Ther Pat       Date:  2016-04-18       Impact factor: 6.674

6.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Takafumi Ikeda; Manabu Minami; Atsushi Kawaguchi; Toshinori Murayama; Masashi Kanai; Yukiko Mori; Shigemi Matsumoto; Shunsuke Chikuma; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Akihiko Ueda; Yuko Hosoe; Satoshi Morita; Masayuki Yokode; Akira Shimizu; Tasuku Honjo; Ikuo Konishi
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

7.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

Authors:  S Muenst; S D Soysal; F Gao; E C Obermann; D Oertli; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2013-06-12       Impact factor: 4.872

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Authors:  Silvia Darb-Esfahani; Catarina Alisa Kunze; Hagen Kulbe; Jalid Sehouli; Stephan Wienert; Judith Lindner; Jan Budczies; Michael Bockmayr; Manfred Dietel; Carsten Denkert; Ioana Braicu; Korinna Jöhrens
Journal:  Oncotarget       Date:  2016-01-12

Review 10.  Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

Authors:  Gloria Mittica; Sofia Genta; Massimo Aglietta; Giorgio Valabrega
Journal:  Int J Mol Sci       Date:  2016-07-20       Impact factor: 5.923

View more
  21 in total

Review 1.  Targeting of the tumor immune microenvironment by metformin.

Authors:  Zihong Wu; Caidie Zhang; Masoud Najafi
Journal:  J Cell Commun Signal       Date:  2021-10-05       Impact factor: 5.908

2.  Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.

Authors:  Yu Rebecca Miao; Kaushik N Thakkar; Jin Qian; Mihalis S Kariolis; Wei Huang; Saravanan Nandagopal; Teddy Tat Chi Yang; Anh N Diep; Gerald Maxwell Cherf; Yu Xu; Eui Jung Moon; Yiren Xiao; Haizea Alemany; Tiane Li; Wenhua Yu; Bo Wei; Erinn B Rankin; Amato J Giaccia
Journal:  Clin Cancer Res       Date:  2021-05-19       Impact factor: 13.801

Review 3.  The Role of NcRNAs to Regulate Immune Checkpoints in Cancer.

Authors:  Yicun Jiang; Leilei Zhao; Yiwen Wu; Sijun Deng; Pu Cao; Xiaoyong Lei; Xiaoyan Yang
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

4.  Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer.

Authors:  Hirokazu Matsushita; Kosei Hasegawa; Sho Sato; Daisuke Shintani; Yukari Kobayashi; Nao Fujieda; Akira Yabuno; Tadaaki Nishikawa; Keiichi Fujiwara; Kazuhiro Kakimi
Journal:  BMC Cancer       Date:  2022-04-21       Impact factor: 4.638

5.  Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Authors:  Niclas C Blessin; Ronald Simon; Martina Kluth; Kristine Fischer; Claudia Hube-Magg; Wenchao Li; Georgia Makrypidi-Fraune; Björn Wellge; Tim Mandelkow; Nicolaus F Debatin; Doris Höflmayer; Maximilian Lennartz; Guido Sauter; Jakob R Izbicki; Sarah Minner; Franziska Büscheck; Ria Uhlig; David Dum; Till Krech; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Eike-Christian Burandt; Stefan Steurer; Waldemar Wilczak; Andrea Hinsch
Journal:  Dis Markers       Date:  2019-01-10       Impact factor: 3.434

Review 6.  Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma.

Authors:  Karishma R Rajani; Lucas P Carlstrom; Ian F Parney; Aaron J Johnson; Arthur E Warrington; Terry C Burns
Journal:  Front Oncol       Date:  2019-02-22       Impact factor: 6.244

7.  Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer.

Authors:  Paul Buderath; Esther Schwich; Christina Jensen; Peter A Horn; Rainer Kimmig; Sabine Kasimir-Bauer; Vera Rebmann
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

8.  Association between BTLA polymorphisms and susceptibility to esophageal squamous cell carcinoma in the Chinese population.

Authors:  Rui Cao; Weifeng Tang; Shuchen Chen
Journal:  J Clin Lab Anal       Date:  2020-02-15       Impact factor: 2.352

Review 9.  Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis.

Authors:  Anusha Thadi; Marian Khalili; William F Morano; Scott D Richard; Steven C Katz; Wilbur B Bowne
Journal:  Vaccines (Basel)       Date:  2018-08-10

10.  BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes.

Authors:  Yu-Li Chen; Han-Wei Lin; Chung-Liang Chien; Yen-Ling Lai; Wei-Zen Sun; Chi-An Chen; Wen-Fang Cheng
Journal:  J Immunother Cancer       Date:  2019-11-21       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.